Find out how genome sequencing has emerged and what the future holds for one of biotech's most important tools.

Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.

Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago ...

Researchers from University of California San Diego have linked a bacterial toxin called colibactin to the increase in early-onset cases of colorectal cancer.

Genomics company, Integrated DNA Technologies, is rewriting the future of genomics, pioneering new innovations in a bold move ...

Prostate cancer is the second-leading cause of cancer deaths among men in the United States and the rate of men diagnosed with advanced disease has been growing in recent years. 1 Veracyte estimates ...

Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals ...

According to its backers, MAGIC-I is Ireland's first clinical study of its type in cancer care and will harness "the power of ...

MAGIC-I, which is Ireland’s first clinical study of genomics approaches in cancer care, will seek to establish the processes ...

Using the Ultima Genomics’ (CA, USA) lower-cost WGS platform and the known mutational patterns in patient tumors as a guide, ...

The overall uptake of broad genomic profiling in patients with metastatic cancers remains low, despite guideline ...

MAGIC-I, the country's first clinical study of genomics approaches in cancer care, is set to revolutionise childhood cancer ...